KOD

Kodiak Sciences Inc

Feb 04 • 04:00PM ET

22.38

-1.65 -6.87 %

Healthcare • Biotechnology • USA • NASD

Today, 7:07 AMKodiak Sciences announces that final Phase 1b APEX end-of-study results for KSI-101 in macular edema secondary to inflammation show continued robust anatomic and visual benefits and confirms active enrollment and new topline data timelines for its KSI-101, tarcocimab and KSI-501 Phase 3 programs.

Peers: REGN NVAX VRTX ALNY NBIX BIIB BLUE CRSP GILD IONS

| Held by: VTI XBI IWM VXF IBB IWN DWAS SCHA VTWO FESM

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-4.12	Insider Own	6.65%	Shs Outstand	61.05M	Perf Week	-14.15%
Market Cap	1.37B	Forward P/E	-	EPS next Y	-3.39	Insider Trans	179.78%	Shs Float	56.99M	Perf Month	-10.48%
Enterprise Value	1.46B	PEG	-	EPS next Q	-1.01	Inst Own	76.11%	Short Float	12.51%	Perf Quarter	20.58%
Income	-217.34M	P/S	-	EPS this Y	-25.23%	Inst Trans	4.98%	Short Ratio	8.38	Perf Half Y	176.64%
Sales	0.00M	P/B	50.06	EPS next Y	19.10%	ROA	-73.58%	Short Interest	7.13M	Perf YTD	-19.96%
Book/sh	0.45	P/C	18.97	EPS next 5Y	3.43%	ROE	-207.92%	52W High	31.18 -28.22%	Perf Year	284.54%
Cash/sh	1.18	P/FCF	-	EPS past 3/5Y	13.38% -21.78%	ROIC	-124.81%	52W Low	1.92 1065.62%	Perf 3Y	187.66%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	9.43% 8.29%	Perf 5Y	-82.55%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-12.93%	Oper. Margin	-	ATR (14)	2.20	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.78	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	39.10	Recom	1.86
Dividend Gr. 3/5Y	- -	Current Ratio	1.78	EPS Q/Q	-39.20%	SMA20	-14.34%	Beta	2.64	Target Price	35.50
Payout	-	Debt/Eq	6.85	Sales Q/Q	-	SMA50	-12.41%	Rel Volume	0.83	Prev Close	24.03
Employees	109	LT Debt/Eq	6.35	Earnings	Nov 13 AMC	SMA200	68.92%	Avg Volume	850.88K	Price	22.38
IPO	Oct 04, 2018	Option/Short	Yes / Yes	EPS/Sales Surpr.	-11.85% -	Trades		Volume	707,718	Change	-6.87%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-11-25	Upgrade	H.C. Wainwright	Neutral → Buy	$24
Oct-24-25	Upgrade	JP Morgan	Neutral → Overweight	$24
Sep-25-25	Upgrade	Barclays	Underweight → Equal Weight	$17
Sep-22-25	Initiated	Jefferies	Buy	$15
Aug-14-25	Upgrade	JP Morgan	Underweight → Neutral	$15
Dec-09-24	Upgrade	Jefferies	Hold → Buy	$20
Sep-05-24	Initiated	H.C. Wainwright	Neutral	$3
Dec-11-23	Resumed	Goldman	Sell	$2
Nov-17-23	Upgrade	CapitalOne	Equal Weight → Overweight	$7 → $12
Jul-27-23	Downgrade	UBS	Buy → Neutral	$15 → $4
Jul-25-23	Downgrade	JP Morgan	Neutral → Underweight
Jul-25-23	Downgrade	Chardan Capital Markets	Buy → Neutral
Jul-24-23	Downgrade	Jefferies	Buy → Hold
Jul-24-23	Downgrade	CapitalOne	Overweight → Equal Weight	$7
Nov-15-22	Initiated	CapitalOne	Overweight	$24
Aug-02-22	Downgrade	Citigroup	Neutral → Sell	$6
Feb-24-22	Downgrade	JP Morgan	Overweight → Neutral	$90 → $21
Feb-11-22	Initiated	Goldman	Buy	$70
Feb-02-22	Upgrade	JP Morgan	Neutral → Overweight	$124 → $90
May-11-21	Upgrade	ROTH Capital	Neutral → Buy	$155 → $149

Show Previous Ratings

Today 07:00AM	Final APEX Phase 1b Clinical Results for Kodiak's KSI-101 in Macular Edema Secondary to Inflammation to be Presented at Angiogenesis 2026 (PR Newswire) -6.87%
Jan-07-26 08:19PM	Kodiak Sciences to Present at 44th Annual J.P. Morgan Healthcare Conference (PR Newswire) +8.06%
Dec-30-25 08:45AM	The Biggest IPO of the Year Prompts Huge Insider Buy (24/7 Wall St.)
Dec-22-25 10:11AM	What Awaits These 4 Biotech Stocks That More Than Doubled in 2025 (Zacks) +10.04%
Dec-18-25 08:26PM	Kodiak Sciences Announces Closing of $184 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares (PR Newswire)
10:55PM	Loading…
Dec-16-25 10:55PM	Kodiak Sciences Announces Pricing of Upsized Public Offering of Common Stock (PR Newswire) +11.77%
Dec-15-25 04:01PM	Kodiak Sciences Announces Proposed Public Offering of Common Stock (PR Newswire)
Nov-14-25 07:36AM	Kodiak Q3 Loss Wider Than Expected, Pipeline Development in Focus (Zacks)
Nov-13-25 04:05PM	Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2025 Financial Results (PR Newswire) -6.81%
Nov-12-25 05:48PM	Kodiak Sciences to Present at Upcoming Investor Conferences (PR Newswire)
Nov-05-25 07:00AM	Follow-up data for Kodiak's KSI-101 from the APEX study showed continued strengthening of clinical effect (=90% of patients achieving absence of intraretinal and subretinal fluid) through week 20 in macular edema secondary to inflammation (MESI) (PR Newswire)
Sep-15-25 07:00AM	New data for Kodiak's KSI-101 from the APEX study reinforce its clinically meaningful vision gains and rapid retinal drying in macular edema secondary to inflammation (MESI) (PR Newswire)
Sep-12-25 11:30AM	Why Is Kodiak Sciences (KOD) Down 1.2% Since Last Earnings Report? (Zacks) -6.75%
Sep-02-25 08:00AM	Kodiak Sciences to Participate in Upcoming Scientific Conferences Highlighting KSI-101 in Patients with Macular Edema Secondary to Inflammation (MESI) (PR Newswire)
Aug-29-25 03:05PM	Jim Cramer on Kodiak Sciences: "That's a Pure Spec Stock" (Insider Monkey)
07:52PM	Loading…
Aug-26-25 07:52PM	Lightning Round: Oklo goes up every time there's a good headline, buy Oklo, says Jim Cramer (CNBC TV)
Aug-19-25 02:18PM	Kodiak Sciences to Present at American Chemical Society Fall 2025 (PR Newswire) -15.73%
Aug-14-25 11:41AM	Kodiak Q2 Loss Wider Than Expected, Pipeline Development in Focus (Zacks) +16.47%
Aug-13-25 04:00PM	Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2025 Financial Results (PR Newswire)
Jul-10-25 08:00AM	Kodiak Sciences to Host Investor R&D Day on July 16, 2025 (PR Newswire)
Jun-25-25 04:45PM	Kodiak Sciences to Present KSI-101 Highlights at 2025 Congress of the International Ocular Inflammation Society (PR Newswire)
Jun-24-25 05:51AM	Age-Related Vision Dysfunction Market Research 2025-2035 \| Kodiak Sciences, Genentech, and AbbVie Drive Innovations Through Advanced, Sustainable Solutions (GlobeNewswire)
Jun-13-25 11:30AM	Why Is Kodiak Sciences (KOD) Up 10.5% Since Last Earnings Report? (Zacks) +5.43%
May-29-25 09:32PM	Kodiak Sciences to Present at 2025 Jefferies Global Healthcare Conference (PR Newswire)
May-15-25 11:04AM	Kodiak Q1 Loss Wider Than Expected, Pipeline Development in Focus (Zacks) -15.48%
May-14-25 04:15PM	Kodiak Sciences Announces Recent Business Highlights and First Quarter 2025 Financial Results (PR Newswire)
May-01-25 11:43PM	Kodiak Sciences Data at ARVO 2025 Highlight Power and Versatility of ABC Platform in Addressing Complex Multifactorial Ocular Diseases (PR Newswire) +6.90%
Apr-01-25 09:35AM	Down -28.08% in 4 Weeks, Here's Why You Should You Buy the Dip in Kodiak Sciences (KOD) (Zacks) -8.73%
Mar-28-25 09:45AM	Kodiak Q4 Loss Narrower Than Expected, Pipeline Development in Focus (Zacks)
Mar-27-25 04:01PM	Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results (PR Newswire)
03:58PM	Loading…
Mar-26-25 03:58PM	Is Kodiak Sciences Inc. (KOD) The Hot Biotech Stock Under $5? (InsiderMonkey) -6.08%
Mar-10-25 04:39PM	Kodiak Sciences Completes Enrollment in Second Registrational Trial of Tarcocimab in Patients with Diabetic Retinopathy (PR Newswire)
Feb-04-25 07:30AM	Kodiak Sciences to Present at Glaucoma 360 New Horizons Forum 2025 (PR Newswire)
Jan-13-25 04:26PM	Heres Why Kodiak Sciences Inc. (KOD) Is Skyrocketing (Insider Monkey) -6.13%
Jan-07-25 06:00AM	Kodiak Sciences to Present at 43rd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-09-24 09:18PM	Nona Biosciences and Kodiak Sciences Partner on Next-Generation Antibody Therapies for Ophthalmic Diseases (PR Newswire) +29.63%
12:33PM	Eye-Disease Focused Kodiak Sciences Is A Promising 'Turnaround Story For 2025': Analyst Upgrades Stock (Benzinga)
Nov-25-24 09:55AM	Kodiak Sciences Inc. (KOD) Just Flashed Golden Cross Signal: Do You Buy? (Zacks)
Nov-14-24 04:01PM	Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2024 Financial Results (PR Newswire)
Nov-11-24 06:15AM	Kodiak Sciences to Participate in Upcoming Investor Conferences (PR Newswire) +8.54%
Oct-14-24 05:35PM	Kodiak Sciences to Present at Innovate Retina 2024 (PR Newswire)
Sep-23-24 06:00AM	Kodiak Sciences to Host Investor R&D Day Today at 10:30am Eastern Time (PR Newswire)
Sep-17-24 04:05PM	Kodiak Sciences to Host Investor R&D Day on September 23, 2024 in New York City (PR Newswire)
Sep-13-24 11:30AM	Why Is Kodiak Sciences (KOD) Down 8.1% Since Last Earnings Report? (Zacks) +13.87%
Aug-16-24 10:42AM	Kodiak (KOD) Q2 Loss Narrower Than Expected, Pipeline in Focus (Zacks)
Aug-14-24 09:54PM	KOD Stock Earnings: Kodiak Sciences Beats EPS for Q2 2024 (InvestorPlace)
04:01PM	Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2024 Financial Results (PR Newswire)
Jul-10-24 12:00PM	All You Need to Know About Kodiak Sciences (KOD) Rating Upgrade to Buy (Zacks)
Jun-20-24 08:23AM	Should You Hold Kodiak Sciences (KOD) Stock in Your Portfolio? (Zacks)
Jun-14-24 11:30AM	Why Is Kodiak Sciences (KOD) Down 26.2% Since Last Earnings Report? (Zacks)
May-29-24 04:36PM	Kodiak Sciences to Present at Upcoming Investor and Clinical Conferences (PR Newswire)
May-16-24 12:51PM	Kodiak (KOD) Q1 Loss Narrower Than Expected, Pipeline in Focus (Zacks)
May-15-24 10:55PM	KOD Stock Earnings: Kodiak Sciences Beats EPS for Q1 2024 (InvestorPlace)
04:01PM	Kodiak Sciences Announces Recent Business Highlights and First Quarter 2024 Financial Results (PR Newswire)
May-14-24 07:31AM	Kodiak Sciences dosing subjects in Phase III trial of diabetic retinopathy drug (Clinical Trials Arena)
May-13-24 07:32PM	Kodiak Sciences Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer in Diabetic Retinopathy (PR Newswire) +6.09%
May-02-24 04:30PM	Kodiak Sciences Data at ARVO 2024 Highlight Depth of Early and Late-Phase Retina Pipeline including Advancements with High Drug-Antibody-Ratio Therapeutics Built on Kodiak's Antibody Biopolymer Conjugate (ABC) Platform (PR Newswire)
Apr-04-24 12:09PM	Kodiak (KOD) Counts on Tarcocimab Program Despite Setbacks (Zacks)
Apr-01-24 05:04PM	Kodiak Sciences Inc. (NASDAQ:KOD) Q4 2023 Earnings Call Transcript (Insider Monkey) -15.40%
12:00PM	Kodiak (KOD) Stock Falls on Q4 Earnings Miss, Pipeline in Focus (Zacks)
Mar-29-24 10:36AM	Q4 2023 Kodiak Sciences Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-28-24 11:53AM	KOD Stock Earnings: Kodiak Sciences Misses EPS for Q4 2023 (InvestorPlace) -29.40%
08:32AM	Kodiak Sciences Inc (KOD) Posts Q4 and Full Year 2023 Financial Results (GuruFocus.com)
06:30AM	Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results (PR Newswire)
Mar-26-24 06:15AM	Kodiak Sciences to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Business Updates Webcast on March 28, 2024 (PR Newswire) +16.01%
Jan-30-24 06:30AM	Kodiak Sciences Announces Upcoming Presentation of First Time Results of KSI-501ABC Phase 1 Study at the Angiogenesis, Exudation, and Degeneration 2024 Virtual Meeting (PR Newswire) -8.58%
Jan-04-24 04:15PM	Kodiak Sciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-14-23 11:30AM	Kodiak Sciences Inc. (KOD) Up 43.6% Since Last Earnings Report: Can It Continue? (Zacks) +6.21%
Nov-21-23 04:15PM	Kodiak Sciences to Present at the 6th Annual Evercore ISI HealthCONx Conference (PR Newswire) -7.41% +6.67%
Nov-15-23 08:00AM	Kodiak (KOD) Beats Q3 Earnings, Provides Pipeline Updates (Zacks) +5.21%
Nov-14-23 06:09PM	Kodiak Sciences Inc (KOD) Reports Q3 2023 Financial Results: Net Loss Narrows, R&D Expenses ... (GuruFocus.com) +6.67%
04:01PM	Kodiak Sciences Announces Third Quarter 2023 Financial Results and Recent Business Highlights (PR Newswire)
Nov-06-23 05:00AM	Kodiak reboots tarcocimab tedromer development program following strong positive results in Phase 3 diabetic retinopathy GLOW study and following dialogue with US regulatory authorities on a regulatory pathway for BLA submission (PR Newswire) -13.56%
Nov-01-23 11:21PM	KODIAK SCIENCES ANNOUNCES FIRST TIME PRESENTATION OF PRIMARY ENDPOINT DATA FROM TARCOCIMAB TEDROMER PHASE 3 GLOW STUDY IN PATIENTS WITH DIABETIC RETINOPATHY AT AMERICAN ACADEMY OF OPHTHALMOLOGY ANNUAL MEETING (PR Newswire) +6.21% +37.01%
Oct-17-23 01:44AM	Lonza Warns on 2024 Profitability Hit From Lost Moderna Revenue (The Wall Street Journal)
Oct-11-23 06:00AM	Kodiak Sciences Announces Upcoming Presentations at the 56th Annual Scientific Meeting of the Retina Society (PR Newswire)
Sep-13-23 11:30AM	Kodiak Sciences Inc. (KOD) Down 19.9% Since Last Earnings Report: Can It Rebound? (Zacks)
Sep-08-23 06:00AM	Kodiak Sciences to Present at the Morgan Stanley 21st Annual Global Healthcare Conference (PR Newswire)
Sep-07-23 06:00AM	New one-year results for Kodiak's tarcocimab tedromer in the pivotal BEACON trial reinforce durability signal and demonstrate matched efficacy and comparable safety and tolerability in retinal vein occlusion (PR Newswire)
Aug-16-23 10:26AM	Kodiak (KOD) Q2 Earnings Miss, New Lead Candidate in Focus (Zacks)
Aug-14-23 07:31PM	While dollars continue to flow into biotech, companies cut more jobs (American City Business Journals) -6.81% -9.97%
04:01PM	Kodiak Sciences Announces Second Quarter 2023 Financial Results and Recent Business Highlights (PR Newswire)
08:34AM	Should You Buy Kodiak Sciences (KOD) Ahead of Earnings? (Zacks)
07:15AM	3 Biotech Stocks Poised to Beat Q2 Earnings Estimates (Zacks)
Aug-02-23 10:09AM	Eli Lilly (LLY) to Report Q2 Earnings: What's in the Cards? (Zacks) +5.33%
Jul-27-23 02:30AM	4 big analyst cuts: Carvana 'well above our increased target,' says Morgan Stanley (Investing.com) -10.49%
Jul-26-23 06:42AM	Kodiak Sciences Inc. (NASDAQ:KOD) Is Expected To Breakeven In The Near Future (Simply Wall St.) -10.74%
Jul-25-23 09:16AM	Kodiak (KOD) Down as Late-Stage DME Studies Fail (Zacks) -7.98%
Jul-24-23 06:26AM	CORRECTED-UPDATE 1-Kodiak Sciences scraps development of eye disorder drug (Reuters) -45.88%
06:09AM	Kodiak Sciences scraps development of eye disorder drug (Reuters)
06:00AM	Kodiak Sciences Announces Topline Results from its Phase 3 Studies of Tarcocimab Tedromer in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema and Provides Update on Tarcocimab Development Program (PR Newswire)
Jun-14-23 11:30AM	Why Is Kodiak Sciences Inc. (KOD) Up 62.9% Since Last Earnings Report? (Zacks)
May-30-23 04:15PM	Kodiak Sciences to Present at Upcoming Investor Conferences (PR Newswire)
11:14AM	Kodiak (KOD) Advances With Tarcocimab Amid Stiff Competition (Zacks)
May-16-23 07:44AM	Kodiak's (KOD) Q1 Earnings Miss, Pipeline in Focus, Stock Up (Zacks) +10.44%
May-15-23 04:01PM	Kodiak Sciences Announces First Quarter 2023 Financial Results and Recent Business Highlights (PR Newswire) +12.61%
Apr-27-23 11:30AM	Why Is Kodiak Sciences Inc. (KOD) Down 26.3% Since Last Earnings Report? (Zacks)
Apr-21-23 07:30AM	Kodiak Sciences Announces Upcoming Presentations on its Product and Research Pipeline at ARVO 2023 Annual Meeting (PR Newswire)
Apr-11-23 06:29AM	We're Keeping An Eye On Kodiak Sciences' (NASDAQ:KOD) Cash Burn Rate (Simply Wall St.)
Apr-04-23 01:16PM	Kodiak (KOD) Treats First Patient in Diabetic Macular Edema Study (Zacks) -8.56%

Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutics for retinal diseases. Its product pipeline includes KSI-301 for wet AMD, KSI-301 for diabetic eye disease, KSI-501 for DME and uveitis, KSI-201 for resistant wet AMD, and KSI-401 for dry AMD. The company was founded by Stephen A. Charles and Victor Perlroth in 2009 and is headquartered in Palo Alto, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BAKER BROS. ADVISORS LP	Director	Dec 18 '25	Buy	23.00	2,608,696	60,000,008	18,358,772	Dec 19 04:06 PM
BORGESON JOHN A.	See Remarks	Jun 17 '25	Sale	3.65	723	2,640	183,316	Jun 17 08:15 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

KOD

Kodiak Sciences Inc

Upgrade your FINVIZ experience